In 2025, global Healthcare and Life Sciences M&A rebounded decisively, with deal volume rising to 585 transactions and total announced value reaching $269.3 billion, nearly double 2024 levels, supported by stronger pricing and larger upfront commitments. Value creation was concentrated in biopharma, diagnostics, and data-driven services, while services and software drove volume, accentuating a market favouring scaled, de-risked, and commercially advanced assets.

This recovery was exemplified by five noticeable transactions: Pfizer’s $7.6 billion acquisition of Metsera, plus up to $2.4 billion in CVRs, targeting obesity and cardiometabolic diseases through GLP 1 and amylin programs; Merck’s $10 billion acquisition of Verona Pharma, anchored by the approved COPD therapy Ohtuvayre; Sanofi’s $9.5 billion acquisition of Blueprint Medicines to strengthen oncology and immunology with approved and late stage small molecule assets; Thermo Fisher Scientific’s $8.9 billion upfront acquisition of Clario Holdings, with additional deferred and contingent payments, expanding its digital clinical trial and biopharma services platform; and Merck’s $9.2 billion acquisition of Cidara Therapeutics, adding the approved antifungal Rezzayo and a late stage infectious disease and oncology pipeline.

These deals highlight 2025’s key themes of increased capital deployment, a focus on late-stage and approved assets, scalable platforms, and strategic investment in high-growth disease areas, including obesity, oncology, infectious diseases, respiratory, and immunology, establishing a strong foundation for continued M&A momentum into 2026.

In 2025, global Healthcare and Life Sciences M&A rebounded strongly, with deal volume rising to 585 transactions from 466 in 2024 and total announced value reaching $269.3 billion, including contingents, or $236.9 billion excluding contingents. This nearly doubled 2024 levels of $140.8 billion and $124.5 billion, reflecting a clear recovery in both activity and capital deployment. Deal economics also strengthened, with average upfront cash and equity increasing to $1.4 billion from $764 million. In comparison, the median upfront rose to $275 million from $175 million, indicating broader pricing momentum beyond a handful of large transactions. Across 2024 and 2025 combined, the market recorded 1,051 deals totaling $410.1 billion, including contingents, or $361.4 billion excluding contingents, with 2025 accounting for most value growth and improved upfront terms.

 

 M&A by Subsector

In 2025, Healthcare and Life Sciences M&A expansion was broad-based by deal volume, while value was concentrated in Biopharma and Diagnostics. Manufacturing Tech and Other led activity with 203 deals, up 41 percent from 144 in 2024, but total value was broadly flat at $30 billion versus $31.4 billion. Diagnostics, Sequencing, Omics, and Tools saw a sharp step-up, with deal count rising to 154 from 113 and announced value jumping to $74.8 billion from $15.6 billion, making it one of the largest value increases of the year. Biopharma Therapeutics and Discovery Platforms remained stable by volume at 136 deals versus 134, but value more than doubled to $146.8 billion from $63.9 billion, accounting for over half of the total 2025 M&A value and emerging as the primary value driver.

Medtech, Devices, Digital Therapeutics, and Wearables saw higher activity in 2025, with deal count increasing to 92 from 75, but total value declined to $17.8 billion from $29.9 billion, indicating smaller average transaction sizes despite greater volume. Overall, the market expanded sharply in 2025, recording 585 deals totaling $269.4 billion, compared with 466 deals and $140.8 billion in 2024. Across 2024 and 2025 combined, subsector totals reached 270 deals and $210.7 billion in Biopharma, 267 deals and $90.4 billion in Diagnostics, 347 deals and $61.3 billion in Manufacturing and Other, and 167 deals and $47.7 billion in Medtech.

 

M&A Activity by Target Company Type

In 2025, global Healthcare and Life Sciences M&A was weighted toward services and software in terms of deal volume, while biopharma and diagnostics accounted for most value creation and the largest increases in transaction size.

 

Private Biopharma M&A Targets

In 2025, deal activity declined to 75 transactions from 81 in 2024, but total announced value increased to $40.1 billion from $30.2 billion a larger average deal sizes in 2025, with higher transaction values offsetting the modest drop in volume.

 

Small-Mid Cap Biopharma M&A Targets

In 2025, deal activity rose to 59 transactions from 41 in 2024, while total announced value surged to $105.5 billion from $33.4 billion. A clear rebound in both volume and capital deployment, driven by larger acquisitions for scaled assets.

 

Medtech & Device M&A Targets

In 2025, M&A activity increased to 42 deals from 28 in 2024, with total announced value rising to $32.9 billion from $22.2 billion signalling improved momentum in 2025.

 

Diagnostics M&A Targets

In 2025, deal volume was largely flat at 24 transactions versus 23 in 2024, but total announced value surged to $43.2 billion from just $2.2 billion. This divergence indicates that 2025 results were driven by a small number of very large acquisitions rather than an increase in deal activity.

 

CDMO and Services M&A Targets

In 2025, deal activity remained strong at 133 transactions, but total value declined to $8.8 billion from $24.5 billion in 2024 across 138 deals, indicating ongoing consolidation at smaller average deal sizes.

 

Health Service / IT / Software M&A Targets

In 2025, deal activity surged to 237 transactions with total value rising to $31.5 billion, reflecting strong consolidation in services and software. In 2024, the sector recorded 142 deals worth $23.4 billion. The growth in 2025 was largely volume-driven, with higher deal counts contributing to a moderate rise in total value.

Across 2024 and 2025 combined, subsector totals were: Private Biopharma 156 deals / $70.4 billion, Small & Mid-Cap Bio 100 / $138.9 billion, Medtech & Device 70 / $55.1 billion, Diagnostics 47 / $45.4 billion, CDMO & Services 271 / $33.3 billion, and Healthcare Service/Software 379 / $54.9 billion.

 

 SPACs and Reverse Mergers

In 2025, SPACs and reverse mergers fell to 19 deals but generated $6.5 billion in total M&A value, including contingents ($5.4 billion excluding contingents). In 2024, activity was higher at 26 deals with $7.1 billion, including contingents (and $6.5 billion excluding contingents). Despite the lower 2025 deal count, upfront economics strengthened materially, with the average upfront cash & equity rising to $601 million (from $433 million) and the median jumping to $330 million (from $120 million).

Prominent M&A’s Global Healthcare and Life Sciences 2025

Pfizer acquiring Metsera – September 2026

Pfizer acquired Metsera, a clinical-stage obesity and cardiometabolic company, in a transaction that highlights strong demand for late stage GLP 1 and amylin assets. Metsera’s pipeline is led by MET 097i, a Phase II injectable GLP-1 receptor agonist, MET 233i, a Phase I monthly amylin analog evaluated alone and in combination, and two oral GLP-1 candidates approaching clinical entry, alongside next-generation combination programs. After a competitive process involving a rival bid from Novo Nordisk, Pfizer increased its offer and signed a definitive agreement. Under the final terms, Pfizer paid $65.60 per share in cash, valuing Metsera at $7.6 billion, and granted contingent value rights of up to $20.65 per share, or approximately $2.4 billion in aggregate. The CVRs are tied to clinical and regulatory milestones, including Phase III initiation and FDA approvals for MET 097i and the MET 097i plus MET 233i combination through 2031. Earlier proposals included $47.50 per share plus up to $22.50 per share in CVRs, and a revised $60.00 per share offer with up to $10.00 per share in CVRs, reflecting stepped-up pricing during negotiations. The acquisition was completed on November 13, 2025.

Merck acquiring Verona Pharma – July 2026

Merck acquired Verona Pharma, adding a recently approved COPD therapy with potential for lifecycle expansion. Verona’s lead asset, Ohtuvayre (ensifentrine), is a first-in-class dual PDE3 and PDE4 inhibitor approved in June 2024 for maintenance treatment of COPD in adults. The drug also has Phase II programs in non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma, with a fixed-dose combination with glycopyrrolate in early development for COPD. Under the terms of the transaction, Verona shareholders received $107 per ADS, equivalent to $13.375 per ordinary share, valuing the company at approximately $10 billion. The acquisition was approved by the UK High Court on October 6, 2025, and completed on October 7, 2025.

Sanofi acquiring Blueprint Medicines – June 2025

Sanofi acquired Blueprint Medicines to strengthen its oncology and immunology portfolio with approved and late-stage small-molecule assets. Blueprint’s portfolio is anchored by Ayvakit, approved for gastrointestinal stromal tumor and systemic mastocytosis, supported by Phase III elenestinib for systemic mastocytosis and Phase II BLU 808 for chronic urticaria and allergic rhinoconjunctivitis, with planned expansion into asthma and other mast cell-driven diseases. Sanofi paid $129 per share in cash, representing a 27 percent one-day premium and valuing Blueprint at approximately $9.5 billion, including $9.1 billion upfront. Shareholders are eligible for up to $400 million in milestone payments, comprising $2 per share tied to a clinical development milestone and $4 per share tied to a regulatory milestone for BLU 808. The acquisition was completed on July 18, 2025.

Thermo Fisher Scientific acquiring Clario Holdings – October 2025

Thermo Fisher Scientific agreed to acquire Clario Holdings, a privately held provider of digital clinical trial endpoint data, technology platforms, and global trial operations, strengthening Thermo Fisher’s data and digital capabilities within biopharma services. Upon closing, Clario will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services segment. The transaction includes approximately $8.9 billion in upfront cash at closing, $125 million in deferred consideration payable in January 2027, and up to $400 million in contingent consideration tied to Clario’s performance in 2026 and 2027. The deal is expected to close by mid 2026, be immediately accretive to adjusted EPS by $0.45 in the first year and generate around $175 million in annual synergies within five years.

Merck acquiring Cidara Therapeutics – November 2025

Merck acquired Cidara Therapeutics, adding an approved antifungal product and a diversified infectious disease and oncology pipeline built on its Cloudbreak drug Fc conjugate platform. Cidara’s portfolio is led by Rezzayo, approved for candidemia and invasive candidiasis, and CD 388, a Phase III long-acting influenza prevention candidate, alongside earlier-stage programs in fungal infections, oncology, HIV, and SARS-related viruses. Under the terms of the transaction, Merck paid $221.50 per share in cash, representing a 108.9 percent one-day premium and valuing Cidara at approximately $9.2 billion. The acquisition was completed on January 7, 2026.

 

Also check out Global Healthcare and Life Sciences R&D Partnerships – 2025 Review